DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. The long term use of colchicine is established for FMF and the prophylaxis of gout flares but the safety and efficacy of repeat treatment for gout flares has not been evaluated. The dosing regimens for COLCRYS are different for each indication and must be individualized.The recommended dosage of COLCRYS depends on the patients age, renal function, hepatic function, and use of co-administered drugs [see Dose Modification for Co-administration of Interacting Drugs (2.4) ].COLCRYS tablets are administered orally, without regard to meals.COLCRYS is not an analgesic medication and should not be used to treat pain from other causes.. oGout Flares: Prophylaxis of Gout Flares: 0.6 mg once or twice daily in adults and adolescents older than 16 years of age (2.1). Maximum dose 1.2 mg/day. Treatment of Gout Flares: 1.2 mg (2 tablets) at the first sign of gout flare followed by 0.6 mg (1 tablet) one hour later (2.1).oFMF: Adults and Children older than 12 years 1.2 2.4 mg; Children to 12 years 0.9 1.8 mg; Children to years 0.3 1.8 mg (2.2, 2.3).Give total daily dose in one or two divided doses (2.2).Increase or decrease the dose as indicated and as tolerated in increments of 0.3 mg/day, not to exceed the maximum recommended daily dose (2.2). Colchicine tablets are administered orally, without regard to meals.See full prescribing information for dose adjustment regarding patients with impaired renal function (2.5), impaired hepatic function (2.6), the patients age (2.3, 8.5), or use of co-administered drugs (2.4).. oGout Flares: Prophylaxis of Gout Flares: 0.6 mg once or twice daily in adults and adolescents older than 16 years of age (2.1). Maximum dose 1.2 mg/day. Treatment of Gout Flares: 1.2 mg (2 tablets) at the first sign of gout flare followed by 0.6 mg (1 tablet) one hour later (2.1).. Prophylaxis of Gout Flares: 0.6 mg once or twice daily in adults and adolescents older than 16 years of age (2.1). Maximum dose 1.2 mg/day.. Treatment of Gout Flares: 1.2 mg (2 tablets) at the first sign of gout flare followed by 0.6 mg (1 tablet) one hour later (2.1).. oFMF: Adults and Children older than 12 years 1.2 2.4 mg; Children to 12 years 0.9 1.8 mg; Children to years 0.3 1.8 mg (2.2, 2.3).Give total daily dose in one or two divided doses (2.2).Increase or decrease the dose as indicated and as tolerated in increments of 0.3 mg/day, not to exceed the maximum recommended daily dose (2.2). Give total daily dose in one or two divided doses (2.2).. Increase or decrease the dose as indicated and as tolerated in increments of 0.3 mg/day, not to exceed the maximum recommended daily dose (2.2).. 2.1 Gout Flares. Prophylaxis of Gout Flares:The recommended dosage of COLCRYS for prophylaxis of gout flares for adults and adolescents older than 16 years of age is 0.6 mg once or twice daily. The maximum recommended dose for prophylaxis of gout flares is 1.2 mg/day.. Treatment of Gout Flares:The recommended dose of COLCRYS for treatment of gout flare is 1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. Higher doses have not been found to be more effective. The maximum recommended dose for treatment of gout flares is 1.8 mg over 1 hour period. COLCRYS may be administered for treatment of gout flare during prophylaxis at doses not to exceed 1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. Wait 12 hours and then resume the prophylactic dose. 2.2 FMF. The recommended dosage of COLCRYS for FMF in adults is 1.2 mg to 2.4 mg daily.COLCRYS should be increased as needed to control disease and as tolerated in increments of 0.3 mg/day to maximum recommended daily dose. If intolerable side effects develop, the dose should be decreased in increments of 0.3 mg/day. The total daily COLCRYS dose may be administered in one to two divided doses.. 2.3 Recommended Pediatric Dosage. Prophylaxis and Treatment of Gout Flares:COLCRYS is not recommended for pediatric use in prophylaxis or treatment of gout flares.. FMF:The recommended dosage of COLCRYS for FMF in pediatric patients years of age and older is based on age. The following daily doses may be given as single or divided dose twice daily:o Children - years: 0.3 mg to 1.8 mg dailyo Children - 12 years: 0.9 mg to 1.8 mg dailyo Adolescents older than 12 years: 1.2 mg to 2.4 mg daily. Children - years: 0.3 mg to 1.8 mg daily. Children - 12 years: 0.9 mg to 1.8 mg daily. Adolescents older than 12 years: 1.2 mg to 2.4 mg daily. 2.4 Dose Modification for Co-administration of Interacting Drugs. Concomitant Therapy:Co-administration of COLCRYS with drugs known to inhibit CYP3A4 and/or P-glycoprotein (P-gp) increases the risk of colchicine-induced toxic effects (Table 1). If patients are taking or have recently completed treatment with drugs listed in Table within the prior 14 days, the dose adjustments are as shown on the table below [see DRUG INTERACTIONS (7) ].Table COLCRYS Dose Adjustment for Co-administration with Interacting Drugs if no Alternative AvailableFor magnitude of effect on colchicine plasma concentrations [see Pharmacokinetics (12.3) Strong CYP3A4 InhibitorsPatients with renal or hepatic impairment should not be given COLCRYS in conjunction with strong CYP3A4 or P-gp inhibitors [see CONTRAINDICATIONS (4) ].DrugNoted or Anticipated OutcomeGout FlaresFMFProphylaxis of Gout FlaresTreatment of Gout FlaresOriginal Intended DosageAdjusted DoseOriginal Intended DosageAdjusted DoseOriginal Intended DosageAdjusted DoseAtazanavirClarithromycinDarunavir/RitonavirWhen used in combination with Ritonavir, see dosing recommendations for strong CYP3A4 inhibitors [see CONTRAINDICATIONS (4) ]. IndinavirItraconazole KetoconazoleLopinavir/Ritonavir NefazodoneNelfinavirRitonavirSaquinavir TelithromycinTipranavir/Ritonavir Significant increase in colchicine plasma levels; fatal colchicine toxicity has been reported with clarithromycin, strong CYP3A4 inhibitor. Similarly, significant increase in colchicine plasma levels is anticipated with other strong CYP3A4 inhibitors.0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other day1.2 mg(2 tablets) followed by 0.6 mg (1 tablet) hour later. Dose to be repeated no earlier than days.0.6 mg(1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 1.2 2.4 mgMaximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)Moderate CYP3A4 InhibitorsDrugNoted or Anticipated OutcomeGout FlaresFMFProphylaxis of Gout FlaresTreatment of Gout FlaresOriginal Intended DosageAdjusted DoseOriginal Intended DosageAdjusted DoseOriginal Intended DosageAdjusted DoseAmprenavir AprepitantDiltiazem Erythromycin Fluconazole Fosamprenavir (pro-drug ofAmprenavir)Grapefruit JuiceVerapamilSignificant increase in colchicine plasma concentration is anticipated. Neuromuscular toxicity has been reported with diltiazem and verapamil interactions.0.6 mg twice day 0.6 mg once day0.3 mg twice day or 0.6 mg once day 0.3 mg once day1.2 mg(2 tablets) followed by 0.6 mg (1 tablet) hour later. Dose to be repeated no earlier than days.1.2 mg(2 tablets) 1 dose. Dose to be repeated no earlier than days.Maximum daily dose of 1.2 2.4 mg.Maximum daily dose of 1.2 mg (may be given as 0.6 mg twice day)P-gp InhibitorsDrugNoted or Anticipated OutcomeGout FlaresFMFProphylaxis of Gout FlaresTreatment of Gout FlaresOriginal Intended DosageAdjusted DoseOriginal Intended DosageAdjusted DoseOriginal Intended DosageAdjusted DoseCyclosporine RanolazineSignificant increase in colchicine plasma levels; fatal colchicine toxicity has been reported with cyclosporine, P-gp inhibitor. Similarly, significant increase in colchicine plasma levels is anticipated with other P-gp inhibitors.0.6 mg twice day 0.6 mg once day 0.3 mg once day 0.3 mg once every other day1.2 mg(2 tablets) followed by 0.6 mg (1 tablet) hour later. Dose to be repeated no earlier than days.0.6 mg(1 tablet) 1 dose. Dose to be repeated no earlier than days.Maximum daily dose of 1.2 2.4 mgMaximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)Table COLCRYS Dose Adjustment for Co-administration with Protease InhibitorsProtease InhibitorClinical Commentw/Colchicine Prophylaxis of Gout Flaresw/Colchicine -Treatment of Gout Flaresw/Colchicine Treatment of FMFAtazanavir sulfate(Reyataz)Patients with renal or hepatic impairment should not be given colchicine with Reyataz.Original doseAdjusted dose0.6 mg (1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other dayDarunavir (Prezista)Patients with renal or hepatic impairment should not be given colchicine with Prezista/ritonavir.Original doseAdjusted dose0.6 mg (1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other dayFosamprenavir (Lexiva) with RitonavirPatients with renal or hepatic impairment should not be given colchicine with Lexiva/ritonavir.Original doseAdjusted dose0.6 mg (1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other dayFosamprenavir (Lexiva)Patients with renal or hepatic impairment should not be given colchicine with Lexiva/ritonavir.Original doseAdjusted dose1.2 mg (2 tablets) 1 dose. Dose to be repeated no earlier than days.Maximum daily dose of 1.2 mg (may be given as 0.6 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg twice day or 0.6 mg once day 0.3 mg once dayIndinavir (Crixivan)Patients with renal or hepatic impairment should not be given colchicine with Crixivan.Original doseAdjusted dose0.6 mg (1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other dayLopinavir/Ritonavir (Kaletra)Patients with renal or hepatic impairment should not be given colchicine with Kaletra.Original doseAdjusted dose0.6 mg (1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other dayNelfinavir mesylate (Viracept)Patients with renal or hepatic impairment should not be given colchicine with Viracept.Original doseAdjusted dose0.6 mg (1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other dayRitonavir (Norvir)Patients with renal or hepatic impairment should not be given colchicine with Norvir.Original doseAdjusted dose0.6 mg (1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other daySaquinavir mesylate (Invirase)Patients with renal or hepatic impairment should not be given colchicine with Invirase/ritonavir.Original doseAdjusted dose0.6 mg (1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other dayTipranavir (Aptivus)Patients with renal or hepatic impairment should not be given colchicine with Aptivus/ritonavir.Original doseAdjusted dose0.6 mg (1 tablet) 1 dose, followed by 0.3 mg (1/2 tablet) hour later. Dose to be repeated no earlier than days.Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice day)0.6 mg twice day 0.6 mg once day0.3 mg once day 0.3 mg once every other dayTreatment of gout flares with COLCRYS is not recommended in patients receiving prophylactic dose of COLCRYS and CYP3A4 inhibitors.. 2.5 Dose Modification in Renal Impairment. Colchicine dosing must be individualized according to the patients renal function [see Renal Impairment (8.6) ]. Clcr in mL/minute may be estimated from serum creatinine (mg/dL) determination using the following formula:Clcr =[140-age (years) weight (kg)] 0.85 for female patients72 serum creatinine (mg/dL). Gout Flares:. Prophylaxis of Gout Flares:For prophylaxis of gout flares in patients with mild (estimated creatinine clearance Clcr 50 80 mL/min) to moderate (Clcr 30 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, the starting dose should be 0.3 mg per day and any increase in dose should be done with close monitoring. For the prophylaxis of gout flares in patients undergoing dialysis, the starting doses should be 0.3 mg given twice week with close monitoring [see Clinical Pharmacology (12.3) and Renal Impairment (8.6) ].. Treatment of Gout Flares:For treatment of gout flares in patients with mild (Clcr 50 80 mL/min) to moderate (Clcr 30 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, while the dose does not need to be adjusted for the treatment of gout flares, treatment course should be repeated no more than once every weeks. For patients with gout flares requiring repeated courses consideration should be given to alternate therapy. For patients undergoing dialysis, the total recommended dose for the treatment of gout flares should be reduced to single dose of 0.6 mg (1 tablet). For these patients, the treatment course should not be repeated more than once every weeks [see Clinical Pharmacology (12.3) and Renal Impairment (8.6) ].Treatment of gout flares with COLCRYS is not recommended in patients with renal impairment who are receiving COLCRYS for prophylaxis.. FMF: Caution should be taken in dosing patients with moderate and severe renal impairment and in patients undergoing dialysis. For these patients, the dosage should be reduced [see Clinical Pharmacology (12.3) ]. Patients with mild (Clcr 50 80 mL/min) and moderate (Clcr 30 50 mL/min) renal impairment should be monitored closely for adverse effects of COLCRYS. Dose reduction may be necessary. For patients with severe renal failure (Clcr less than 30 mL/minute), start with 0.3 mg/day; any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine [see Renal Impairment (8.6) ]. For patients undergoing dialysis, the total recommended starting dose should be 0.3 mg (half tablet) per day. Dosing can be increased with close monitoring. Any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine [see Clinical Pharmacology (12.3) and Renal Impairment (8.6) ].. 2.6 Dose Modification in Hepatic Impairment. Gout Flares Prophylaxis of Gout Flares: For prophylaxis of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. Dose reduction should be considered for the prophylaxis of gout flares in patients with severe hepatic impairment [see Hepatic Impairment (8.7) ].. Treatment of Gout Flares:For treatment of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, for the treatment of gout flares in patients with severe impairment while the dose does not need to be adjusted, but treatment course should be repeated no more than once every weeks. For these patients, requiring repeated courses for the treatment of gout flares, consideration should be given to alternate therapy [see Hepatic Impairment (8.7) ].Treatment of gout flares with COLCRYS is not recommended in patients with hepatic impairment who are receiving COLCRYS for prophylaxis.. FMF:Patients with mild to moderate hepatic impairment should be monitored closely for adverse effects of colchicine. Dose reduction should be considered in patients with severe hepatic impairment [see Hepatic Impairment (8.7) ].

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. Prophylaxis of Gout Flares: The most commonly reported adverse reaction in clinical trials for the prophylaxis of gout was diarrhea. Treatment of Gout Flares: The most common adverse reactions reported in the clinical trial for gout were diarrhea (23%) and pharyngolaryngeal pain (3%). FMF: Most common adverse reactions (up to 20%) are abdominal pain, diarrhea, nausea, and vomiting. These effects are usually mild, transient, and reversible upon lowering the dose (6). To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc. at 1-877-825-3327 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. Prophylaxis of Gout Flares:The most commonly reported adverse reaction in clinical trials of colchicine for the prophylaxis of gout was diarrhea.. Treatment of Gout Flares:The most common adverse reactions reported in the clinical trial with COLCRYS for treatment of gout flares were diarrhea (23%) and pharyngolaryngeal pain (3%).. FMF:Gastrointestinal tract adverse effects are the most frequent side effects in patients initiating COLCRYS, usually presenting within 24 hours, and occurring in up to 20% of patients given therapeutic doses. Typical symptoms include cramping, nausea, diarrhea, abdominal pain, and vomiting. These events should be viewed as dose-limiting if severe as they can herald the onset of more significant toxicity.. 6.1 Clinical Trials Experience in Gout. Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of drug cannot be directly compared to rates in the clinical studies of another drug, and may not predict the rates observed in broader patient population in clinical practice.In randomized, double-blind, placebo-controlled trial in patients with gout flare, gastrointestinal adverse reactions occurred in 26% of patients using the recommended dose (1.8 mg over hour) of COLCRYS compared to 77% of patients taking non-recommended high-dose (4.8 mg over hours) of colchicine and 20% of patients taking placebo. Diarrhea was the most commonly reported drug-related gastrointestinal adverse event. As shown in Table 3, diarrhea is associated with COLCRYS treatment. Diarrhea was more likely to occur in patients taking the high-dose regimen than the low-dose regimen. Severe diarrhea occurred in 19% and vomiting occurred in 17% of patients taking the non-recommended high-dose colchicine regimen but did not occur in the recommended low-dose COLCRYS regimen.Table Number (%) of Patients with at Least One Drug-Related Treatment Emergent Adverse Events with an Incidence of >= 2% of Patients in Any Treatment GroupMedDRA System Organ ClassMedDRA Preferred TermCOLCRYS DosePlacebo(N=59)n (%)High (N=52)n (%)Low (N=74)n (%)Number of Patients with at Least One Drug-Related TEAE40 (77)27 (37)16 (27)Gastrointestinal Disorders40 (77)19 (26)12 (20) Diarrhea40 (77)17 (23)8 (14) Nausea9 (17)3 (4)3 (5) Vomiting9 (17)00 Abdominal Discomfort002 (3)General Disorders and Administration Site Conditions4 (8)1 (1)1 (2) Fatigue2 (4)1 (1)1 (2)Metabolic and Nutrition Disorders03 (4)2 (3) Gout03 (4)1 (2)Nervous System Disorders1 (2)1 (1.4)2 (3) Headache1 (2)1 (1)2 (3)Respiratory Thoracic Mediastinal Disorders1 (2)2 (3)0 Pharyngolaryngeal Pain1 (2)2 (3)0. 6.2 Postmarketing Experience. Serious toxic manifestations associated with colchicine include myelosuppression, disseminated intravascular coagulation, and injury to cells in the renal, hepatic, circulatory, and central nervous systems.These most often occur with excessive accumulation or overdosage [see OVERDOSAGE (10) ].The following adverse reactions have been reported with colchicine. These have been generally reversible upon temporarily interrupting treatment or lowering the dose of colchicine. Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia. Neurological: sensory motor neuropathy. Dermatological: alopecia, maculopapular rash, purpura, rash. Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting. Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia. Hepatobiliary: elevated AST, elevated ALT. Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis. Reproductive: azoospermia, oligospermia.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. The mechanism by which COLCRYS exerts its beneficial effect in patients with FMF has not been fully elucidated; however, evidence suggests that colchicine may interfere with the intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediates activation of interleukin-1. Additionally, colchicine disrupts cytoskeletal functions through inhibition of -tubulin polymerization into microtubules, and consequently prevents the activation, degranulation, and migration of neutrophils thought to mediate some gout symptoms.. 12.3 Pharmacokinetics. AbsorptionIn healthy adults, COLCRYS is absorbed when given orally, reaching mean Cmax of 2.5 ng/mL (range 1.1 to 4.4 ng/mL) in to hours (range 0.5 to hours) after single dose administered under fasting conditions. Following oral administration of COLCRYS given as 1.8 mg colchicine over hour to healthy, young adults under fasting conditions, colchicine appears to be readily absorbed, reaching mean maximum plasma concentrations of 6.2 ng/mL at median 1.81 hours (range: 1.0 to 2.5 hours). Following administration of the non-recommended high-dose regimen (4.8 mg over hours), mean maximal plasma concentrations were 6.8 ng/mL, at median 4.47 hours (range: 3.1 to 7.5 hours).After 10 days on regimen of 0.6 mg twice daily, peak concentrations are 3.1 to 3.6 ng/mL (range 1.6 to 6.0 ng/mL), occurring 1.3 to 1.4 hours post-dose (range 0.5 to 3.0 hours). Mean pharmacokinetic parameter values in healthy adults are shown in Table below.Table Mean (%CV) Pharmacokinetic Parameters in Healthy Adults Given COLCRYSCmax (colchicine ng/mL)Tmax Tmax mean (range) (h)Vd/F (L)CL/F (L/hr)t1/2 (h)COLCRYS 0.6 mg Single Dose (N=13)2.5 (28.7)1.5 (1.0 3.0)341.5 (54.4)54.1 (31.0)--COLCRYS 0.6 mg b.i.d. 10 days (N=13)3.6 (23.7)1.3 (0.5 3.0)1150 (18.7)30.3 (19.0)26.6 (16.3)CL= Dose/AUC0-t (Calculated from mean values)Vd CL/Ke (Calculated from mean values)In some subjects, secondary colchicine peaks are seen, occurring between and 36 hours post-dose and ranging from 39% to 155% of the height of the initial peak. These observations are attributed to intestinal secretion and reabsorption and/or biliary recirculation. Absolute bioavailability is reported to be approximately 45%.Administration of COLCRYS with food has no effect on the rate of colchicine absorption, but did decrease the extent of colchicine by approximately 15%. This is without clinical significance.. DistributionThe mean apparent volume of distribution in healthy young volunteers was approximately to L/kg. Colchicine binding to serum protein is low, 39 +- 5%, primarily to albumin regardless of concentration. Colchicine crosses the placenta (plasma levels in the fetus are reported to be approximately 15% of the maternal concentration). Colchicine also distributes into breast milk at concentrations similar to those found in the maternal serum [see Pregnancy (8.1) and Nursing Mothers (8.3) ].. MetabolismColchicine is demethylated to two primary metabolites, 2-O-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively), and one minor metabolite, 10-O-demethylcolchicine (also known as colchiceine). In vitro studies using human liver microsomes have shown that CYP3A4 is involved in the metabolism of colchicine to 2- and 3-DMC. Plasma levels of these metabolites are minimal (less than 5% of parent drug). Elimination/ExcretionIn healthy volunteers (n=12) 40 65% of mg orally administered colchicine was recovered unchanged in urine. Enterohepatic recirculation and biliary excretion are also postulated to play role in colchicine elimination. Following multiple oral doses (0.6 mg twice daily), the mean elimination half-lives in young healthy volunteers (mean age 25 to 28 years of age) is 26.6 to 31.2 hours. Colchicine is substrate of P-gp.. Extracorporeal Elimination: Colchicine is not removed by hemodialysis.. Special PopulationsThere is no difference between men and women in the pharmacokinetic disposition of colchicine.. Pediatric Patients: Pharmacokinetics of colchicine was not evaluated in pediatric patients.. Elderly: Pharmacokinetics of colchicine has not been determined in elderly patients. published report described the pharmacokinetics of mg oral colchicine tablet in four elderly women compared to six young healthy males. The mean age of the four elderly women was 83 years (range 75 93), mean weight was 47 kg (38 61 kg) and mean creatinine clearance was 46 mL/min (range 25 75 mL/min). Mean peak plasma levels and AUC of colchicine were two times higher in elderly subjects compared to young healthy males. However, it is possible that the higher exposure in the elderly subjects was due to decreased renal function. Renal impairment: Pharmacokinetics of colchicine in patients with mild and moderate renal impairment is not known. published report described the disposition of colchicine (1 mg) in young adult men and women with FMF who had normal renal function or end-stage renal disease requiring dialysis. Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hrs vs 4.4 hrs) as compared to subjects with FMF and normal renal function [see Dose Modification in Renal Impairment (2.5) and Renal Impairment (8.6) ].. Hepatic impairment: Published reports on the pharmacokinetics of IV colchicine in patients with severe chronic liver disease, as well as those with alcoholic or primary biliary cirrhosis, and normal renal function suggest wide inter-patient variability. In some subjects with mild to moderate cirrhosis, the clearance of colchicine is significantly reduced and plasma half-life prolonged compared to healthy subjects. In subjects with primary biliary cirrhosis, no consistent trends were noted [see Dose Modification in Hepatic Impairment (2.6) and Hepatic Impairment (8.7) ]. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).. Drug interactions:. In vitro drug interactions: In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 activity. In vivo drug interactions: The effects of co-administration of other drugs with COLCRYS on Cmax, AUC, and Cmin are summarized in Table (effect of other drugs on colchicine) and Table (effect of colchicine on other drugs). For information regarding clinical recommendations, see Table in Dose Modification for Co-administration of Interacting Drugs [see Dose Modification for Co-administration of Interacting Drugs (2.4) ].Table Drug Interactions: Pharmacokinetic Parameters for COLCRYS (colchicine, USP) tablets in the Presence of the Co-Administered DrugCo-administered DrugDose of Co-administered Drug (mg)Dose of COLCRYS (mg)N% Change in Colchicine Concentrations from Baseline(Range: Min Max)Cmax AUC0-t Cyclosporine100 mgsingle-dose0.6 mgsingle-dose23270.0(62.0 to 606.9)259.0(75.8 to 511.9)Clarithromycin250 mg BID,7 days0.6 mgsingle-dose23227.2(65.7 to 591.1)281.5(88.7 to 851.6)Ketoconazole200 mg BID,5 days0.6 mgsingle-dose24101.7(19.6 to 219.0)212.2(76.7 to 419.6)Ritonavir100 mg BID,5 days0.6 mgsingle-dose18184.4(79.2 to 447.4)296.0(53.8 to 924.4)Verapamil240 mg daily,5 days0.6 mgsingle-dose2440.1(-47.1 to 149.5)103.3(-9.8 to 217.2)Diltiazem240 mg daily,7 days0.6 mgsingle-dose2044.2(-46.0 to 318.3)93.4(-30.2 to 338.6)Azithromycin500 mg 1 day, then250 mg 4 days0.6 mgsingle-dose2121.6 (-41.7 to 222.0)57.1(-24.3 to 241.1)Grapefruit Juice240 mL BID,4 days0.6 mgsingle-dose21-2.55(-53.4 to 55.0)-2.36(-46.4 to 62.2)Estrogen-containing oral contraceptives: In healthy female volunteers given ethinyl estradiol and norethindrone (Ortho-Novum(R) 1/35) co-administered with COLCRYS (0.6 mg b.i.d. 14 days), hormone concentrations are not affected.In healthy volunteers given theophylline co-administered with COLCRYS (0.6 mg b.i.d. 14 days), theophylline concentrations were not affected.Table Drug Interactions: Pharmacokinetic Parameters for Co-Administration of Drug in the Presence of COLCRYS (colchicine, USP) tabletsCo-administered DrugDose of Co-administered Drug (mg)Dose of COLCRYS (mg)N% Change in Co-Administered Drug Concentrations from Baseline(Range: Min Max)Cmax AUC0-t Theophylline300 mg (elixir) single-dose0.6 mg BID 14 days271.6(-30.4 to 23.1)1.6(-28.5 to 27.1)Ethinyl Estradiol (Ortho-Novum(R) 1/35)21-Day Cycle (Active Treatment) 7-Day Placebo0.6 mg BID 14 days27Conducted in healthy adult females -6.7(-40.3 to 44.7)-3.0AUC (-25.3 to 24.9)Norethindrone (Ortho-Novum(R) 1/35)0.94(-37.3 to 59.4)-1.6 (-32.0 to 33.7).

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. The evidence for the efficacy of colchicine in patients with chronic gout is derived from the published literature. Two randomized clinical trials assessed the efficacy of colchicine 0.6 mg twice day for the prophylaxis of gout flares in patients with gout initiating treatment with urate lowering therapy. In both trials, treatment with colchicine decreased the frequency of gout flares. The efficacy of low dosage regimen of oral colchicine (COLCRYS total dose 1.8 mg over hour) for treatment of gout flares was assessed in multicenter, randomized, double-blind, placebo-controlled, parallel group, week, dose comparison study. Patients meeting American College of Rheumatology criteria for gout were randomly assigned to three groups: high-dose colchicine (1.2 mg, then 0.6 mg hourly 6 hours [4.8 mg total]); low-dose colchicine (1.2 mg, then 0.6 mg in hour [1.8 mg total] followed by placebo doses hourly); or placebo (2 capsules, then capsule hourly 6 hours). Patients took the first dose within 12 hours of the onset of the flare and recorded pain intensity (11-point Likert scale) and adverse events over 72 hours. The efficacy of colchicine was measured based on response to treatment in the target joint, using patient self assessment of pain at 24 hours following the time of first dose as recorded in the diary. responder was one who achieved at least 50% reduction in pain score at the 24-hour post-dose assessment relative to the pre-treatment score and did not use rescue medication prior to the actual time of 24-hour post-dose assessment.Rates of response were similar for the recommended low-dose treatment group (38%) and the non-recommended high-dose group (33%) but were higher as compared to the placebo group (16%) as shown in Table 8.Table Number (%) of Responders Based on Target Joint Pain Score at 24 Hours Post First Dose COLCRYS Dose Responders (%)Placebon (%)(n=58)% Differences in ProportionLow-dose(n=74)High-dose(n=52)Low-dose vs Placebo(95% CI)High-dose vs Placebo(95% CI)28 (38%)17 (33%)9 (16%)22 (8, 37)17 (1, 33)Figure below shows the percentage of patients achieving varying degrees of improvement in pain from baseline at 24 hours.Figure 1Pain Relief on Low and High Doses of COLCRYS and Placebo (Cumulative). The evidence for the efficacy of colchicine in patients with FMF is derived from the published literature. Three randomized, placebo-controlled studies were identified. The three placebo-controlled studies randomized total of 48 adult patients diagnosed with FMF and reported similar efficacy endpoints as well as inclusion and exclusion criteria.One of the studies randomized 15 patients with FMF to 6-month crossover study during which patients discontinued due to study non-compliance. The 10 patients completing the study experienced attacks over the course of 90 days while treated with colchicine compared to 59 attacks over the course of 90 days while treated with placebo. Similarly, the second study randomized 22 patients with FMF to 4-month crossover study during which patients discontinued due to lack of efficacy while receiving placebo or study non-compliance. The 13 patients completing the study experienced 18 attacks over the course of 60 days while treated with colchicine compared to 68 attacks over the course of 60 days while treated with placebo. The third study was discontinued after an interim analysis of of the 11 patients enrolled had completed the study; results could not be confirmed.Open-label experience with colchicine in adults and children with FMF is consistent with the randomized, controlled trial experience, and was utilized to support information on the safety profile of colchicine and for dosing recommendations. Figure1.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. AbsorptionIn healthy adults, COLCRYS is absorbed when given orally, reaching mean Cmax of 2.5 ng/mL (range 1.1 to 4.4 ng/mL) in to hours (range 0.5 to hours) after single dose administered under fasting conditions. Following oral administration of COLCRYS given as 1.8 mg colchicine over hour to healthy, young adults under fasting conditions, colchicine appears to be readily absorbed, reaching mean maximum plasma concentrations of 6.2 ng/mL at median 1.81 hours (range: 1.0 to 2.5 hours). Following administration of the non-recommended high-dose regimen (4.8 mg over hours), mean maximal plasma concentrations were 6.8 ng/mL, at median 4.47 hours (range: 3.1 to 7.5 hours).After 10 days on regimen of 0.6 mg twice daily, peak concentrations are 3.1 to 3.6 ng/mL (range 1.6 to 6.0 ng/mL), occurring 1.3 to 1.4 hours post-dose (range 0.5 to 3.0 hours). Mean pharmacokinetic parameter values in healthy adults are shown in Table below.Table Mean (%CV) Pharmacokinetic Parameters in Healthy Adults Given COLCRYSCmax (colchicine ng/mL)Tmax Tmax mean (range) (h)Vd/F (L)CL/F (L/hr)t1/2 (h)COLCRYS 0.6 mg Single Dose (N=13)2.5 (28.7)1.5 (1.0 3.0)341.5 (54.4)54.1 (31.0)--COLCRYS 0.6 mg b.i.d. 10 days (N=13)3.6 (23.7)1.3 (0.5 3.0)1150 (18.7)30.3 (19.0)26.6 (16.3)CL= Dose/AUC0-t (Calculated from mean values)Vd CL/Ke (Calculated from mean values)In some subjects, secondary colchicine peaks are seen, occurring between and 36 hours post-dose and ranging from 39% to 155% of the height of the initial peak. These observations are attributed to intestinal secretion and reabsorption and/or biliary recirculation. Absolute bioavailability is reported to be approximately 45%.Administration of COLCRYS with food has no effect on the rate of colchicine absorption, but did decrease the extent of colchicine by approximately 15%. This is without clinical significance.. DistributionThe mean apparent volume of distribution in healthy young volunteers was approximately to L/kg. Colchicine binding to serum protein is low, 39 +- 5%, primarily to albumin regardless of concentration. Colchicine crosses the placenta (plasma levels in the fetus are reported to be approximately 15% of the maternal concentration). Colchicine also distributes into breast milk at concentrations similar to those found in the maternal serum [see Pregnancy (8.1) and Nursing Mothers (8.3) ].. MetabolismColchicine is demethylated to two primary metabolites, 2-O-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively), and one minor metabolite, 10-O-demethylcolchicine (also known as colchiceine). In vitro studies using human liver microsomes have shown that CYP3A4 is involved in the metabolism of colchicine to 2- and 3-DMC. Plasma levels of these metabolites are minimal (less than 5% of parent drug). Elimination/ExcretionIn healthy volunteers (n=12) 40 65% of mg orally administered colchicine was recovered unchanged in urine. Enterohepatic recirculation and biliary excretion are also postulated to play role in colchicine elimination. Following multiple oral doses (0.6 mg twice daily), the mean elimination half-lives in young healthy volunteers (mean age 25 to 28 years of age) is 26.6 to 31.2 hours. Colchicine is substrate of P-gp.. Extracorporeal Elimination: Colchicine is not removed by hemodialysis.. Special PopulationsThere is no difference between men and women in the pharmacokinetic disposition of colchicine.. Pediatric Patients: Pharmacokinetics of colchicine was not evaluated in pediatric patients.. Elderly: Pharmacokinetics of colchicine has not been determined in elderly patients. published report described the pharmacokinetics of mg oral colchicine tablet in four elderly women compared to six young healthy males. The mean age of the four elderly women was 83 years (range 75 93), mean weight was 47 kg (38 61 kg) and mean creatinine clearance was 46 mL/min (range 25 75 mL/min). Mean peak plasma levels and AUC of colchicine were two times higher in elderly subjects compared to young healthy males. However, it is possible that the higher exposure in the elderly subjects was due to decreased renal function. Renal impairment: Pharmacokinetics of colchicine in patients with mild and moderate renal impairment is not known. published report described the disposition of colchicine (1 mg) in young adult men and women with FMF who had normal renal function or end-stage renal disease requiring dialysis. Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hrs vs 4.4 hrs) as compared to subjects with FMF and normal renal function [see Dose Modification in Renal Impairment (2.5) and Renal Impairment (8.6) ].. Hepatic impairment: Published reports on the pharmacokinetics of IV colchicine in patients with severe chronic liver disease, as well as those with alcoholic or primary biliary cirrhosis, and normal renal function suggest wide inter-patient variability. In some subjects with mild to moderate cirrhosis, the clearance of colchicine is significantly reduced and plasma half-life prolonged compared to healthy subjects. In subjects with primary biliary cirrhosis, no consistent trends were noted [see Dose Modification in Hepatic Impairment (2.6) and Hepatic Impairment (8.7) ]. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).. Drug interactions:. In vitro drug interactions: In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 activity. In vivo drug interactions: The effects of co-administration of other drugs with COLCRYS on Cmax, AUC, and Cmin are summarized in Table (effect of other drugs on colchicine) and Table (effect of colchicine on other drugs). For information regarding clinical recommendations, see Table in Dose Modification for Co-administration of Interacting Drugs [see Dose Modification for Co-administration of Interacting Drugs (2.4) ].Table Drug Interactions: Pharmacokinetic Parameters for COLCRYS (colchicine, USP) tablets in the Presence of the Co-Administered DrugCo-administered DrugDose of Co-administered Drug (mg)Dose of COLCRYS (mg)N% Change in Colchicine Concentrations from Baseline(Range: Min Max)Cmax AUC0-t Cyclosporine100 mgsingle-dose0.6 mgsingle-dose23270.0(62.0 to 606.9)259.0(75.8 to 511.9)Clarithromycin250 mg BID,7 days0.6 mgsingle-dose23227.2(65.7 to 591.1)281.5(88.7 to 851.6)Ketoconazole200 mg BID,5 days0.6 mgsingle-dose24101.7(19.6 to 219.0)212.2(76.7 to 419.6)Ritonavir100 mg BID,5 days0.6 mgsingle-dose18184.4(79.2 to 447.4)296.0(53.8 to 924.4)Verapamil240 mg daily,5 days0.6 mgsingle-dose2440.1(-47.1 to 149.5)103.3(-9.8 to 217.2)Diltiazem240 mg daily,7 days0.6 mgsingle-dose2044.2(-46.0 to 318.3)93.4(-30.2 to 338.6)Azithromycin500 mg 1 day, then250 mg 4 days0.6 mgsingle-dose2121.6 (-41.7 to 222.0)57.1(-24.3 to 241.1)Grapefruit Juice240 mL BID,4 days0.6 mgsingle-dose21-2.55(-53.4 to 55.0)-2.36(-46.4 to 62.2)Estrogen-containing oral contraceptives: In healthy female volunteers given ethinyl estradiol and norethindrone (Ortho-Novum(R) 1/35) co-administered with COLCRYS (0.6 mg b.i.d. 14 days), hormone concentrations are not affected.In healthy volunteers given theophylline co-administered with COLCRYS (0.6 mg b.i.d. 14 days), theophylline concentrations were not affected.Table Drug Interactions: Pharmacokinetic Parameters for Co-Administration of Drug in the Presence of COLCRYS (colchicine, USP) tabletsCo-administered DrugDose of Co-administered Drug (mg)Dose of COLCRYS (mg)N% Change in Co-Administered Drug Concentrations from Baseline(Range: Min Max)Cmax AUC0-t Theophylline300 mg (elixir) single-dose0.6 mg BID 14 days271.6(-30.4 to 23.1)1.6(-28.5 to 27.1)Ethinyl Estradiol (Ortho-Novum(R) 1/35)21-Day Cycle (Active Treatment) 7-Day Placebo0.6 mg BID 14 days27Conducted in healthy adult females -6.7(-40.3 to 44.7)-3.0AUC (-25.3 to 24.9)Norethindrone (Ortho-Novum(R) 1/35)0.94(-37.3 to 59.4)-1.6 (-32.0 to 33.7).

SPL MEDGUIDE SECTION.

MEDICATION GUIDECOLCRYS(KOL-kris)(colchicine) tabletsRead the Medication Guide that comes with COLCRYS before you start taking it and each time you get refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about COLCRYS when you start taking it and at regular checkups.What is the most important information should know about COLCRYSCOLCRYS can cause serious side effects or death if levels of COLCRYS are too high in your body.o Taking certain medicines with COLCRYS can cause your level of COLCRYS to be too high, especially if you have kidney or liver problems.o Tell your healthcare provider about all your medical conditions, including if you have kidney or liver problems. Your dose of COLCRYS may need to be changed.o Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements.o Even medicines that you take for short period of time, such as antibiotics, can interact with COLCRYS and cause serious side effects or death.o Talk to your healthcare provider or pharmacist before taking any new medicine.o Especially tell your healthcare provider if you take: oatazanavir sulfate (Reyataz(R))ocyclosporine (Neoral(R), Gengraf(R), Sandimmune(R))ofosamprenavir (Lexiva(R)) with ritonaviroindinavir (Crixivan(R))oketoconazole (Nizoral(R))onefazodone (Serzone(R))oritonavir (Norvir(R))otelithromycin (Ketek(R))oclarithromycin (Biaxin(R))odarunavir (Prezista(R))ofosamprenavir (Lexiva(R))oitraconazole (Sporanox(R))olopinavir/ritonavir (Kaletra(R))onelfinavir mesylate (Viracept(R))osaquinavir mesylate (Invirase(R))otipranavir (Aptivus(R))Ask your healthcare provider or pharmacist if you are not sure if you take any of the medicines listed above. This is not complete list of all the medicines that can interact with COLCRYS.o Know the medicines you take. Keep list of them and show it to your healthcare provider and pharmacist when you get new medicine.o Keep COLCRYS out of the reach of children.What is COLCRYSCOLCRYS is prescription medicine used to:oprevent and treat gout flares in adultsotreat familial Mediterranean fever (FMF) in adults and children age four or olderCOLCRYS is not pain medicine and it should not be taken to treat pain related to other conditions unless specifically prescribed for those conditions.Who should not take COLCRYSDo not take COLCRYS if you have liver or kidney problems and you take certain other medicines. Serious side effects, including death, have been reported in these patients even when taken as directed. See What is the most important information should know about COLCRYSWhat should tell my healthcare provider before starting COLCRYSSee What is the most important information should know about COLCRYSBefore you take COLCRYS tell your healthcare provider about all your medical conditions including if you:ohave liver or kidney problemsoare pregnant or plan to become pregnant. It is not known if COLCRYS will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.oare breast-feeding or plan to breast-feed. COLCRYS passes into your breast milk. You and your healthcare provider should decide if you will take COLCRYS or breast-feed. If you take COLCRYS and breast-feed, you should talk to your childs healthcare provider about how to watch for side effects in your child.Tell your healthcare provider about all the medicines you take, including ones that you may only be taking for short time, such as antibiotics. See What is the most important information should know about COLCRYS Do not start new medicine without talking to your healthcare provider.Using COLCRYS with certain other medicines, such as cholesterol-lowering medications and digoxin, can affect each other causing serious side effects. Your healthcare provider may need to change your dose of COLCRYS. Talk to your healthcare provider about whether the medications you are taking might interact with COLCRYS, and what side effects to look for.How should take COLCRYSoTake COLCRYS exactly as your healthcare provider tells you to take it. If you are not sure about your dosing, call your healthcare provider.oCOLCRYS can be taken with or without food.oIf you take too much COLCRYS go to the nearest hospital emergency room right away.oDo not stop taking COLCRYS even if you start to feel better, unless your healthcare provider tells you.oYour healthcare provider may do blood tests while you take COLCRYS.oIf you take COLCRYS daily and you miss dose, then take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time. Do not take doses at the same time. oIf you have gout flare while taking COLCRYS daily, report this to your healthcare provider.What should avoid while taking COLCRYSoAvoid eating grapefruit or drinking grapefruit juice while taking COLCRYS. It can increase your chances of getting serious side effects.What are the possible side effects of COLCRYSCOLCRYS can cause serious side effects or even cause death. See What is the most important information should know about COLCRYSGet medical help right away, if you have:oMuscle weakness or painoNumbness or tingling in your fingers or toesoUnusual bleeding or bruisingoIncreased infectionsoFeel weak or tiredoPale or gray color to your lips, tongue, or palms of your handsoSevere diarrhea or vomitingGout Flares: The most common side effect of COLCRYS in people who have gout flares is diarrhea.FMF: The most common side effects of COLCRYS in people who have FMF are abdominal pain, diarrhea, nausea and vomiting.Tell your healthcare provider if you have any side effect that bothers you or that does not go away.These are not all of the possible side effects of COLCRYS. For more information, ask your healthcare provider or pharmacist.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should store COLCRYSo Store COLCRYS at room temperature between 68 and 77F (20 to 25C).o Keep COLCRYS in tightly closed container.o Keep COLCRYS out of the light.Keep COLCRYS and all medicines out of the reach of children.General Information about COLCRYSMedicines are sometimes prescribed for purposes other than those listed in Medication Guide. Do not use COLCRYS for condition for which it was not prescribed. Do not give COLCRYS to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about COLCRYS. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about COLCRYS that is written for healthcare professionals.For more information, go to www.COLCRYS.com or call 1-877-825-3327.What are the ingredients in COLCRYSActive Ingredient: ColchicineInactive Ingredients: carnauba wax, FD&C blue 2, FD&C red 40, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, titanium dioxide, and triacetin.This Medication Guide has been approved by the U.S. Food and Drug Administration.All trademarks are the property of their respective owners.Distributed by:Takeda Pharmaceuticals America, Inc.Deerfield, IL 60015Rev 01, June 2012. Taking certain medicines with COLCRYS can cause your level of COLCRYS to be too high, especially if you have kidney or liver problems.. Tell your healthcare provider about all your medical conditions, including if you have kidney or liver problems. Your dose of COLCRYS may need to be changed.. Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements.. Even medicines that you take for short period of time, such as antibiotics, can interact with COLCRYS and cause serious side effects or death.. Talk to your healthcare provider or pharmacist before taking any new medicine.. Especially tell your healthcare provider if you take:. oatazanavir sulfate (Reyataz(R)). ocyclosporine (Neoral(R), Gengraf(R), Sandimmune(R)). ofosamprenavir (Lexiva(R)) with ritonavir. oindinavir (Crixivan(R)). oketoconazole (Nizoral(R)). onefazodone (Serzone(R)). oritonavir (Norvir(R)). otelithromycin (Ketek(R)). oclarithromycin (Biaxin(R)). odarunavir (Prezista(R)). ofosamprenavir (Lexiva(R)). oitraconazole (Sporanox(R)). olopinavir/ritonavir (Kaletra(R)). onelfinavir mesylate (Viracept(R)). osaquinavir mesylate (Invirase(R)). otipranavir (Aptivus(R)). Know the medicines you take. Keep list of them and show it to your healthcare provider and pharmacist when you get new medicine.. Keep COLCRYS out of the reach of children.. oprevent and treat gout flares in adults. otreat familial Mediterranean fever (FMF) in adults and children age four or older. ohave liver or kidney problems. oare pregnant or plan to become pregnant. It is not known if COLCRYS will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.. oare breast-feeding or plan to breast-feed. COLCRYS passes into your breast milk. You and your healthcare provider should decide if you will take COLCRYS or breast-feed. If you take COLCRYS and breast-feed, you should talk to your childs healthcare provider about how to watch for side effects in your child.. oTake COLCRYS exactly as your healthcare provider tells you to take it. If you are not sure about your dosing, call your healthcare provider.. oCOLCRYS can be taken with or without food.. oIf you take too much COLCRYS go to the nearest hospital emergency room right away.. oDo not stop taking COLCRYS even if you start to feel better, unless your healthcare provider tells you.. oYour healthcare provider may do blood tests while you take COLCRYS.. oIf you take COLCRYS daily and you miss dose, then take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time. Do not take doses at the same time. oIf you have gout flare while taking COLCRYS daily, report this to your healthcare provider.. oAvoid eating grapefruit or drinking grapefruit juice while taking COLCRYS. It can increase your chances of getting serious side effects.. oMuscle weakness or pain. oNumbness or tingling in your fingers or toes. oUnusual bleeding or bruising. oIncreased infections. oFeel weak or tired. oPale or gray color to your lips, tongue, or palms of your hands. oSevere diarrhea or vomiting. Store COLCRYS at room temperature between 68 and 77F (20 to 25C).. Keep COLCRYS in tightly closed container.. Keep COLCRYS out of the light.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. oIn the presence of mild to moderate renal or hepatic impairment, adjustment of dosing is not required for treatment of gout flare, prophylaxis of gout flare, and FMF but patients should be monitored closely (2.5, 8.6).oIn patients with severe renal impairment for prophylaxis of gout flares the starting dose should be 0.3 mg/day, for gout flares no dose adjustment is required but treatment course should be repeated no more than once every weeks. In FMF patients, start with 0.3 mg/day and any increase in dose should be done with close monitoring (2.5, 8.6).oIn patients with severe hepatic impairment, dose reduction may be needed in prophylaxis of gout flares and FMF patients; while dose reduction may not be needed in gout flares, treatment course should be repeated no more than once every weeks (2.5, 2.6, 8.6, 8.7).oFor patients undergoing dialysis, the total recommended dose for prophylaxis of gout flares should be 0.3 mg given twice week with close monitoring. For treatment of gout flares, the total recommended dose should be reduced to 0.6 mg (1 tablet) 1 dose and the treatment course should not be repeated more than once every two weeks. For FMF patients the starting dose should be 0.3 mg per day and dosing can be increased with close monitoring (2.5, 8.6).oPregnancy: Use only if the potential benefit justifies the potential risk to the fetus (8.1).oNursing Mothers: Caution should be exercised when administered to nursing woman (8.3).oGeriatric Use: The recommended dose of colchicine should be based on renal function (2.5, 8.5).. oIn the presence of mild to moderate renal or hepatic impairment, adjustment of dosing is not required for treatment of gout flare, prophylaxis of gout flare, and FMF but patients should be monitored closely (2.5, 8.6).. oIn patients with severe renal impairment for prophylaxis of gout flares the starting dose should be 0.3 mg/day, for gout flares no dose adjustment is required but treatment course should be repeated no more than once every weeks. In FMF patients, start with 0.3 mg/day and any increase in dose should be done with close monitoring (2.5, 8.6).. oIn patients with severe hepatic impairment, dose reduction may be needed in prophylaxis of gout flares and FMF patients; while dose reduction may not be needed in gout flares, treatment course should be repeated no more than once every weeks (2.5, 2.6, 8.6, 8.7).. oFor patients undergoing dialysis, the total recommended dose for prophylaxis of gout flares should be 0.3 mg given twice week with close monitoring. For treatment of gout flares, the total recommended dose should be reduced to 0.6 mg (1 tablet) 1 dose and the treatment course should not be repeated more than once every two weeks. For FMF patients the starting dose should be 0.3 mg per day and dosing can be increased with close monitoring (2.5, 8.6).. oPregnancy: Use only if the potential benefit justifies the potential risk to the fetus (8.1).. oNursing Mothers: Caution should be exercised when administered to nursing woman (8.3).. oGeriatric Use: The recommended dose of colchicine should be based on renal function (2.5, 8.5).. 8.1 Pregnancy. Pregnancy Category CThere are no adequate and well-controlled studies with colchicine in pregnant women. Colchicine crosses the human placenta. While not studied in the treatment of gout flares, data from limited number of published studies found no evidence of an increased risk of miscarriage, stillbirth, or teratogenic effects among pregnant women using colchicine to treat familial Mediterranean fever (FMF). Although animal reproductive and developmental studies were not conducted with COLCRYS, published animal reproduction and development studies indicate that colchicine causes embryofetal toxicity, teratogenicity, and altered postnatal development at exposures within or above the clinical therapeutic range. COLCRYS should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.. 8.2 Labor and Delivery. The effect of colchicine on labor and delivery is unknown.. 8.3 Nursing Mothers. Colchicine is excreted into human milk. Limited information suggests that exclusively breast-fed infants receive less than 10 percent of the maternal weight-adjusted dose. While there are no published reports of adverse effects in breast-feeding infants of mothers taking colchicine, colchicine can affect gastrointestinal cell renewal and permeability. Caution should be exercised and breast-feeding infants should be observed for adverse effects when COLCRYS is administered to nursing woman.. 8.4 Pediatric Use. The safety and efficacy of colchicine in children of all ages with FMF has been evaluated in uncontrolled studies. There does not appear to be an adverse effect on growth in children with FMF treated long-term with colchicine. Gout is rare in pediatric patients, safety and effectiveness of colchicine in pediatric patients has not been established.. 8.5 Geriatric Use. Clinical studies with colchicine for prophylaxis and treatment of gout flares and for treatment of FMF did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient with gout should be cautious, reflecting the greater frequency of decreased renal function, concomitant disease, or other drug therapy [see Dose Modification for Co-administration of Interacting Drugs (2.4) ].. 8.6 Renal Impairment Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Total body clearance of colchicine was reduced by 75% in patients with end-stage renal disease undergoing dialysis.. Prophylaxis of Gout Flares:For prophylaxis of gout flares in patients with mild (estimated creatinine clearance Clcr 50 80 mL/min) to moderate (Clcr 30 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, the starting dose should be 0.3 mg per day and any increase in dose should be done with close monitoring. For the prophylaxis of gout flares in patients undergoing dialysis, the starting doses should be 0.3 mg given twice week with close monitoring [see Dose Modification in Renal Impairment (2.5) ]. Treatment of Gout Flares:For treatment of gout flares in patients with mild (Clcr 50 80 mL/min) to moderate (Clcr 30 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of COLCRYS. However, in patients with severe impairment, while the dose does not need to be adjusted for the treatment of gout flares, treatment course should be repeated no more than once every weeks. For patients with gout flares requiring repeated courses consideration should be given to alternate therapy. For patients undergoing dialysis, the total recommended dose for the treatment of gout flares should be reduced to single dose of 0.6 mg (1 tablet). For these patients, the treatment course should not be repeated more than once every weeks [see Dose Modification in Renal Impairment (2.5) ].. FMFAlthough, pharmacokinetics of colchicine in patients with mild (Clcr 50 80 mL/min) and moderate (Clcr 30 50 mL/min) renal impairment is not known, these patients should be monitored closely for adverse effects of colchicine. Dose reduction may be necessary. In patients with severe renal failure (Clcr less than 30 mL/minute) and end-stage renal disease requiring dialysis, COLCRYS may be started at the dose of 0.3 mg/day. Any increase in dose should be done with adequate monitoring of the patient for adverse effects of COLCRYS [see Pharmacokinetics (12.3) and Dose Modification in Renal Impairment (2.5) ].. 8.7 Hepatic Impairment. The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment, compared to healthy subjects [see Pharmacokinetics (12.3) ].. Prophylaxis of Gout Flares: For prophylaxis of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. Dose reduction should be considered for the prophylaxis of gout flares in patients with severe hepatic impairment [see Dose Modification in Hepatic Impairment (2.6) ].. Treatment of Gout Flares: For treatment of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended COLCRYS dose is not required, but patients should be monitored closely for adverse effects of COLCRYS. However, for the treatment of gout flares in patients with severe impairment while the dose does not need to be adjusted, the treatment course should be repeated no more than once every weeks. For these patients, requiring repeated courses for the treatment of gout flares, consideration should be given to alternate therapy [see Dose Modification in Hepatic Impairment (2.6) ].. FMFIn patients with severe hepatic disease, dose reduction should be considered with careful monitoring [see Pharmacokinetics (12.3) and Dose Modification in Hepatic Impairment (2.6) ].

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. oFatal overdoses have been reported with colchicine in adults and children. Keep COLCRYS out of the reach of children (5.1, 10).oBlood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported (5.2).oMonitor for toxicity and if present consider temporary interruption or discontinuation of colchicine (5.2, 5.3, 5.4, 6, 10).oDrug interaction P-gp and/or CYP3A4 inhibitors: Co-administration of colchicine with P-gp and/or strong CYP3A4 inhibitors has resulted in life-threatening interactions and death (5.3, 7).oNeuromuscular toxicity: Myotoxicity including rhabdomyolysis may occur, especially in combination with other drugs known to cause this effect. Consider temporary interruption or discontinuation of COLCRYS (5.4, 7).. oFatal overdoses have been reported with colchicine in adults and children. Keep COLCRYS out of the reach of children (5.1, 10).. oBlood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported (5.2).. oMonitor for toxicity and if present consider temporary interruption or discontinuation of colchicine (5.2, 5.3, 5.4, 6, 10).. oDrug interaction P-gp and/or CYP3A4 inhibitors: Co-administration of colchicine with P-gp and/or strong CYP3A4 inhibitors has resulted in life-threatening interactions and death (5.3, 7).. oNeuromuscular toxicity: Myotoxicity including rhabdomyolysis may occur, especially in combination with other drugs known to cause this effect. Consider temporary interruption or discontinuation of COLCRYS (5.4, 7).. 5.1 Fatal Overdose. Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [see OVERDOSAGE (10) ]. COLCRYS should be kept out of the reach of children.. 5.2 Blood Dyscrasias. Myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.. 5.3 Drug Interactions. Colchicine is P-gp and CYP3A4 substrate. Life-threatening and fatal drug interactions have been reported in patients treated with colchicine given with P-gp and strong CYP3A4 inhibitors. If treatment with P-gp or strong CYP3A4 inhibitor is required in patients with normal renal and hepatic function, the patients dose of colchicine may need to be reduced or interrupted [see DRUG INTERACTIONS (7) ]. Use of COLCRYS in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors, except fosamprenavir) is contraindicated in patients with renal or hepatic impairment [see CONTRAINDICATIONS (4) ]. 5.4 Neuromuscular Toxicity. Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Concomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, gemfibrozil, fenofibrate, fenofibric acid, or benzafibrate (themselves associated with myotoxicity) or cyclosporine with COLCRYS may potentiate the development of myopathy [see DRUG INTERACTIONS (7) ]. Once colchicine is stopped, the symptoms generally resolve within week to several months.